Huber Capital Management LLC Boosts Stock Position in Kenvue Inc. (NYSE:KVUE)

Huber Capital Management LLC raised its stake in Kenvue Inc. (NYSE:KVUE) by 15.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 169,300 shares of the company’s stock after purchasing an additional 22,900 shares during the quarter. Huber Capital Management LLC’s holdings in Kenvue were worth $3,615,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of KVUE. Paloma Partners Management Co purchased a new position in Kenvue during the third quarter worth about $360,000. Benjamin Edwards Inc. purchased a new position in shares of Kenvue during the 3rd quarter worth approximately $1,323,000. Hilltop Holdings Inc. lifted its holdings in shares of Kenvue by 3.1% in the 3rd quarter. Hilltop Holdings Inc. now owns 80,331 shares of the company’s stock valued at $1,858,000 after buying an additional 2,434 shares during the period. Janus Henderson Group PLC lifted its holdings in shares of Kenvue by 40.6% in the 3rd quarter. Janus Henderson Group PLC now owns 219,576 shares of the company’s stock valued at $5,080,000 after buying an additional 63,400 shares during the period. Finally, Investment Management Corp of Ontario boosted its stake in shares of Kenvue by 48.9% in the third quarter. Investment Management Corp of Ontario now owns 63,627 shares of the company’s stock valued at $1,472,000 after buying an additional 20,900 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Citigroup cut their price objective on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research report on Wednesday, January 15th. UBS Group cut their price target on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a report on Friday, February 7th. Evercore ISI started coverage on shares of Kenvue in a research note on Monday, March 24th. They issued an “in-line” rating and a $25.00 price objective for the company. Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a “buy” rating to a “hold” rating and lowered their target price for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. Finally, Piper Sandler lifted their price target on shares of Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a research report on Monday, February 24th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the company. According to MarketBeat, Kenvue has an average rating of “Hold” and a consensus price target of $24.00.

Kenvue Price Performance

Shares of NYSE:KVUE opened at $23.87 on Thursday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The business’s fifty day moving average price is $22.50 and its two-hundred day moving average price is $22.47. The stock has a market cap of $45.62 billion, a PE ratio of 45.04, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were given a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.44%. The ex-dividend date was Wednesday, February 12th. Kenvue’s dividend payout ratio is presently 154.72%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.